299 related articles for article (PubMed ID: 29579330)
1. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
2. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.
Rosenberg AS; Ruthazer R; Paulus JK; Kent DM; Evens AM; Klein AK
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):684-692.e3. PubMed ID: 27771291
[TBL] [Abstract][Full Text] [Related]
3. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
4. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
6. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
Giraldi E; Provenzi M; Conter V; Colledan M; Bolognini S; Foglia C; Sebastiani R; Fiocchi R; Gianatti A; DʼAntiga L; Rambaldi A
Transplantation; 2016 Feb; 100(2):437-45. PubMed ID: 26270449
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL
Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718
[TBL] [Abstract][Full Text] [Related]
9. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience.
Wójciak M; Gozdowska J; Dęborska-Materkowska D; Perkowska-Ptasińska A; Kosieradzki M; Nazarewski S; Durlik M
Transplant Proc; 2018 Sep; 50(7):2154-2158. PubMed ID: 30177129
[TBL] [Abstract][Full Text] [Related]
11. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes.
Berglund D; Kinch A; Edman E; Backlin C; Enblad G; Larsson E; Molin D; Pauksens K; Sundström C; Baecklund E
Transplantation; 2015 May; 99(5):1036-42. PubMed ID: 25211518
[TBL] [Abstract][Full Text] [Related]
12. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
14. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
Krishnamurthy S; Hassan A; Frater JL; Paessler ME; Kreisel FH
Int J Surg Pathol; 2010 Aug; 18(4):278-85. PubMed ID: 19578050
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant lymphoproliferative disorder in pediatric patients: Survival rates according to primary sites of occurrence and a proposed clinical categorization.
L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Stephens D; Punnett AS; Barton M; Allen UD
Am J Transplant; 2019 Oct; 19(10):2764-2774. PubMed ID: 30884098
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous lymphoproliferative disorders in organ transplant recipients: update 2014.
Seçkin D
G Ital Dermatol Venereol; 2014 Aug; 149(4):401-8. PubMed ID: 25068227
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
18. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
[TBL] [Abstract][Full Text] [Related]
19. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
